| Name | Title | Contact Details |
|---|
Medterra takes pride in providing our customers with the highest quality pure CBD, grown and processed in the USA.
CareerSource Heartland is a not-for-profit corporation that operates as a demand-driven and business focused public-private partnership. Through oversight provided by the local elected officials from DeSoto, Hardee, and Highlands counties, our Board of Directors offer workforce development related growth opportunities to Business Customers and Job Seekers throughout our Tri-County service delivery area. As one of twenty-four Regional Workforce Boards in Florida, we oversee the workforce and talent development activities in the tri-county region, collaborating with numerous private and public sector organizations and businesses to enhance the local economy. Our Board has a diversified membership with a majority of the members from the private (business) sector. The Board also includes representatives from secondary and post-secondary education institutions, Economic Development commissions, and community based organizations.
Creek Nation Div Of Hlth is a Okmulgee, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Thornhill Research Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.